Company profile for Intrommune Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Intrommune is a New York City-based biotechnology company dedicated to simplifying allergy immunotherapy. Intrommune’s core technology enables immunotherapeutic agents to be delivered in a specially formulated toothpaste designed to incorporate and stabilize allergenic proteins, representing a new therapeutic approach for the treatment of peanut and other food allergies. Intrommune is developing the oral mucosal immunothe...
Intrommune is a New York City-based biotechnology company dedicated to simplifying allergy immunotherapy. Intrommune’s core technology enables immunotherapeutic agents to be delivered in a specially formulated toothpaste designed to incorporate and stabilize allergenic proteins, representing a new therapeutic approach for the treatment of peanut and other food allergies. Intrommune is developing the oral mucosal immunotherapy (OMIT) platform for food allergies. It is a long-term solution for the 220 million, including 9 million U.S. adults and 6 million U.S. children, who suffer from this life-altering condition.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
20 W 125th St, New York, 10027
Telephone
Telephone
646-770-2533
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/05/28/3089659/0/en/Intrommune-Therapeutics-Announces-Independent-Editorial-Highlighting-Breakthrough-Safety-Data-for-Novel-Toothpaste-Peanut-Allergy-Treatment.html

GLOBENEWSWIRE
28 May 2025

https://www.globenewswire.com/news-release/2025/02/19/3028992/0/en/Intrommune-Therapeutics-Announces-Publication-of-OMEGA-Study-in-Peanut-Allergic-Adults-in-Annals-of-Allergy-Asthma-Immunology.html

GLOBENEWSWIRE
19 Feb 2025

https://www.globenewswire.com/news-release/2024/05/21/2885719/0/en/Intrommune-Therapeutics-Presents-Oral-Mucosal-Immunotherapy-Updates-at-Leading-Industry-Events.html

GLOBENEWSWIRE
21 May 2024

https://www.globenewswire.com//news-release/2024/03/12/2844737/0/en/Intrommune-Therapeutics-Strengthens-Board-of-Directors-with-Appointments-of-Dr-Jonathan-Rich-and-Hem-Pandya.html

GLOBENEWSWIRE
12 Mar 2024

https://www.globenewswire.com//news-release/2024/02/22/2833802/0/en/Intrommune-Therapeutics-Presents-Supporting-Data-Introducing-a-New-Form-of-Food-Allergy-Treatment.html

GLOBENEWSWIRE
22 Feb 2024

https://www.globenewswire.com//news-release/2024/02/06/2824466/0/en/Intrommune-Therapeutics-To-Present-A-New-Form-Of-Allergy-Treatment-At-The-2024-American-Academy-Of-Allergy-Asthma-Immunology-AAAAI-Annual-Meeting.html

GLOBENEWSWIRE
06 Feb 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty